Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.1%, DAX (0.1%), CAC +0.1%, IBEX +0.1%, MIB +0.5%

May 07 ,2026

  • Synopsis

    • European equity markets set to open broadly flat to higher. Asian equities strengthening Thursday. Japan surging (Nikkei +6%) upon resumption of trade with SoftBank leading tech rally. Tech majors driving Hong Kong. TSMC pushing Taiwan to fresh record high. Crude hovering around lows after dropping 7% on US-Iran peace talk headlines.

    • Markets welcoming signs of fresh momentum in US-Iran peace talks amid reports two sides nearing agreement on 14-point MoU to end war, set in motion 30-day negotiation period and framework for nuclear talks. Trump repeated claim Iran desperate for deal and agreed to abandon nuclear weapons. Publicly, Iran maintaining defiant tone and there is skepticism whether two sides can find common ground on nuclear issue/HEU stockpiles and Iranian demands to control Strait of Hormuz. Some thought also Trump under time constraints to seal agreement before his visit to Beijing.

    • European macro data releases include Germany Mar factory orders, industrial production, Apr construction PMI, France Mar trade balance, Switzerland Apr unemployment rate, Denmark Mar industrial production, Eurozone Mar retail sales, Ireland Apr unemployment rate, UK Apr construction PMI

    • In central banks, Riksbank is expected to leave its benchmark interest rate unchanged at 1.75% with decision at 9:15CET, press conf 11:00. Norges Bank interest rate decision at 10:00CET. No change expected in the 4.00% benchmark interest rate. Russia central bank summary of the last MPC meeting and commentary on the medium-term forecast and Czech central bank is expected to leave its benchmark interest rate unchanged at 3.5% in decision at CET, also releasing Spring economic forecast. Amongst speakers are Austria central bank's Kocher panellist at 8:45CET at St. Gallen Symposium (Tue-Thu), Bank of France's Villeroy speech/Q+A at 9:15CET at the Global Interdependence Center conf and ECB's De Guindos speech at 9:15CET, ECB's Elderson chairs panel at 14:00, EU's Albuquerque speech at 15:30, Estonia central bank's Alber at conf jointly organised by EU Commission and ECB on European Financial Integration. Bundesbank's Theurer interview at 9:00CET at Bundesbank-Symposium. BOE's 2026 BEAR conf 'The Interconnected World' (through Fri) - Lombardelli opening remarks at 9:00BST and chairs panel including ECB's Lane, BOE's Taylor at 13:40, as well as Brussels Economic Forum, speakers/panellist include EU's Dombrovskis at 11:00CET, Latvia central bank's Kazāks at 15:30. ECB's Schnabel delivering 5th Annual Charles Goodhart Lecture at 19:00 CET.

    • In the UK, England local election, Welsh National Assembly election and Scottish Parliament election. Chancellor Merz delivers a speech at the Grand Overseas Day, speaks/Q+A at Chamber of Commerce and Industry Day and will deliver a short address at the Federal Ministry for Digital and Public Sector Innovation (BMDS) to mark its one-year anniversary. Finland's President Stubb hosts German President Steinmeier. EU's Zaharieva participates in the Politico AI&Tech week (Tue-Thu). First day of trading of Silex Microsystems (+SILEX.SS) on Nasdaq Stockholm. Germany Apr new car registrations.

    • Busy on the corporate front, with heavy earnings newsflow. Swiss Re (SREN.SW) topped consensus with strong Q1 profits and improved reinsurance metrics, while Siemens Healthineers (SHL.GR) met earnings expectations but warned on slower future revenue growth. Henkel (HEN3.GR) reports Q1 revenue €4.95B vs consensus €4.95B; Organic Growth +1.7% vs consensus +1.1%. In the UK, Shell (SHEL.LN) and Intercontinental Hotels (IHG.LN) due to report. GSK (GSK.LN) inked a cardiometabolic drug licensing deal worth over $1 billion. Roche (ROP.SW) boosted M&A activity by moving to acquire PathAI in a deal potentially worth over $1 billion upfront and in milestones. Novo Nordisk (NOVO.B.DC) received a key UK endorsement for its blockbuster obesity drug Wegovy. Italy's Nexi (NEXI.IM) confirmed guidance after solid earnings and Telecom Italia (TIT.IM) reports Q1 EBITDA (organic) ex Sparkle €964M vs consensus €973M; reaffirms 2026 guidance. In France, Engie (ENGI.FP) outperformed profit forecasts. Kontron (KTN.GR) disclosed a potential takeover bid, and Essity (ESSITY.B.SS) launched a strategic review of its Consumer Tissue unit. Atlantic Lithium (ALL.LN) agreed to be acquired by Huayou Cobalt (002274.SZ).. Elsewhere, Airbus (AIR.FP) confirmed a major 150-jet order from AirAsia, and Infineon (IFX.GR) and Relx (REL.LN) saw downgrades from brokers.

  • Politics/Macro/World News

    • UK construction activity tumbles as Iran war pushes up costs, RICS survey shows -- Reuters

    • Iran expected to respond Thursday to US proposal for ending war, source says -- CNN

    • Polls open in England, Scotland and Wales for biggest round of elections since 2024 -- BBC

    • Starmer's last-ditch plea as Labour braces for local election disaster -- Independent

  • Top company news

    • Earnings/updates

      • Benelux

        • GLPG.NA (Galapagos) -- reports Q1 EPS €0.21 vs FactSet (€0.82) [3 est, (€1.10)-(0.51)]

        • PHARM.NA (Pharming Group) --reports Q1 EPS ($0.01) vs FactSet $0.00 [3 est, ($0.00)-0.00]

        • AMG.NA (AMG Critical Materials) -- reports Q1 net income $12.2M vs FactSet $5M [1 est]; reiterate FY adj EBITDA guidance range

        • SBMO.NA (SBM Offshore) -- Q1 Trading Update: Directional revenue $3.49B vs year-ago $1.10B

      • DACH

        • SREN.SW (Swiss Re) -- reports Q1 net income $1.51B vs consensus $1.19B; CoR P&C Re 79.5% vs consensus 82.4%; CoRo CoSo 85.1% vs consensus 89.0%

        • SHL.GR (Siemens Healthineers) -- reports Q2 adj EPS €0.53 vs consensus €0.51; adjusts FY26 comparable revenue growth guidance downward

        • HEN3.GR (Henkel) -- reports Q1 revenue €4.95B vs consensus €4.95B; Organic Growth +1.7% vs consensus +1.1%; guides FY26

        • LXS.GR (Lanxess) -- reports Q1 EPS (€0.50) vs consensus (€0.17)

        • AMS.SW (ams-OSRAM) -- reports Q1 EPS (€0.74) ex-items vs FactSet (€0.39) [5 est, (€0.70)-(0.13)]

        • AVOL.SW (Avolta) -- reports Q1 CORE EBITDA CHF190M vs StreetAccount CHF192.3M; reaffirms medium-term outlook

        • VNA.GR (Vonovia) -- reports Q1 EPRA NTA per share €46.57 vs year-ago €46.28; on track towards 2026 guidance of adj. EBITDA €2.95 - €3.05B

        • AAD.GR (Amadeus FiRe) -- reports Q1 EPS (€0.16) vs year-ago €0.18

        • KBX.GR (Knorr-Bremse) -- reports Q1 Operating EBIT €260.8M vs StreetAccount €249.8M; Orders €2.23B vs StreetAccount €2.18B; Confirms FY Guidance

      • Italy

        • TIT.IM (Telecom Italia) -- reports Q1 EBITDA (organic) ex Sparkle €964M vs consensus €973M; reaffirms 2026 guidance

        • ENEL.IM (Enel) -- reports Q1 operational data: total installed capacity 91,856 MW vs year-ago 90,725 MW

        • NEXI.IM (Nexi SpA) -- reports Q1 EBITDA €396.5M vs FactSet €385.0M [4 est, €381-387M]; FY26 guidance confirmed

        • CPR.IM (Davide Campari-Milano) -- reports Q1 revenue €643M vs consensus €645.2M; FY26 outlook is confirmed

      • Nordics

        • ZEAL.DC (Zealand Pharma) -- reports Q1 EPS (DKK5.58) vs FactSet (DKK8.85) [5 est, (DKK9.96)-(7.63)]; reaffirms FY guidance

        • AMBEA.SS (Ambea AB) -- reports Q1 EPS SEK2.03 vs FactSet SEK1.99 [5 est, SEK1.66-2.32]

        • AKRBP.NO (Aker BP) -- reports Q1 EPS $1.20 vs FactSet $0.66 [13 est, $0.47-0.75]

        • SCMN.SW (Swisscom) -- reports Q1 net income CHF332M vs consensus CHF352M; proposes to hike divi from CHF 26 to CHF 27/sh if targets are achieved

        • GN.DC (GN Store Nord) -- updates guidance to reflect Hearing business being treated as discontinued operations

        • GN.DC (GN Store Nord) -- reports Q1 EBITA from cont. ops DKK6M ex-items vs consensus DKK98.5M; financial guidance updated to reflect the carve-out of the Hearing division

        • RECSI.NO (REC Silicon) -- reports Q1 EPS from cont. ops. ($0.04) vs year-ago ($0.04)

        • STERV.FH (Stora Enso) -- reports Q1 EPS €0.05 vs consensus €0.10

        • CHEMM.DC (ChemoMetec) -- reports Q3 EBITDA DKK84.5M vs FactSet DKK74.7M [3 est, DKK63.8-92.3M]

        • SANOMA.FH (Sanoma) -- reports Q1 adjusted EPS (€0.13) vs FactSet (€0.16) [6 est, (€0.19)-(0.14)]

        • VIVA.SS (Viva Wine Group) -- reports Q1 EPS SEK0.29 vs FactSet SEK0.38 [3 est, SEK0.25-0.63]

        • EG7.SS (Enad Global 7) -- reports Q1 adjusted EPS SEK0.11 vs year-ago (SEK0.10)

        • ESSITY.B.SS (Essity) -- reaffirms financial targets of an annual organic sales growth > +3% and an EBITA margin excl. IAC > 15% - CMD

      • Spain

        • ELE.SM (Endesa) -- reports Q1 net income attributable €725M vs FactSet €636.6M

        • ELE.SM (Endesa) -- Follow-up: Endesa reaffirms FY guidance - slides

      • Portugal

        • JMT.PL (Jeronimo Martins) -- reports Q1 net income €119M vs FactSet €119.5M [10 est, €112.7-133M]

        • BCP.PL (Banco Comercial Portugues) -- reports Q1 net income €305.8M vs FactSet €282.5M [10 est, €274-293M]

        • CTT.PL (CTT - Correios de Portugal) -- reports Q1 net income €4.5M vs FactSet €5.9M [2 est, €5-6.8M] (post EU close 6-May)

      • UK

        • DEC.LN (Diversified Energy) -- reports Q1 adjusted EBITDA $287M vs FactSet $252.1M [10 est, $202.9-286.9M]

      • France

        • LR.FP (Legrand) -- reports Q1 net income €334.9M vs consensus €337.3M; FY26 targets confirmed

        • EN.FP (Bouygues) -- reports Q1 Revenue €12.18B vs consensus €12.40B; EBIT €77.0M vs consensus €66.0M

        • ENGI.FP (ENGIE) -- reports Q1 EBIT ex. Nuclear €3.44B vs consensus €3.16B; 2026 guidance confirmed

        • EMEIS.FP (Emeis SA) -- reports Q1 revenue €1.51B

        • TRI.FP (Trigano) -- reports H1 net income €121.3M, +15% vs year-ago €105.7M

      • Also reporting today

        • Earnings

          • Benelux: Titan (TITC.BB), Solvay (SOLB.BB), Eurocommercial Properties (ECMPA.NA)

          • Nordics: Genmab (GMAB.DC), Maersk (MAERSK.B.DC), Jeudan (JDAN.DC), Lån & Spar Bank (LASP.DC), Solar (SOLAR.B.DC), Columbus (COLUM.DC), Gabriel Holding (GABR.DC), Harvia (HARVIA.FH), Musti Group (MUSTI.FH), Oma Savings Bank (OMASP.FH), Etteplan (ETTE.FH), SRV Group (SRV1V.FH), Orthex (ORTHEX.FH), Suominen (SUY1V.FH), Skanska (SKA.B.SS), NOBA Bank Group (NOBA.SS), Loomis (LOOMIS.SS), Sinch (SINCH.SS), MEKO (MEKO.SS), Haypp Group (HAYPP.SS), Truecaller (TRUE.B.SS), Rugvista Group (RUG.SS), I-Tech (ITECH.SS), Rottneros (RROS.SS), Fractal Gaming Group (FRACTL.SS), Sensys Gatso Group (SGG.SS), Mentice (MNTC.SS), Greater Than (GREAT.SS), Active Biotech (ACTI.SS), Immunovia (IMMNOV.SS), Himalaya Shipping (HSHP.NO), DNO (DNO.NO), SpareBank 1 SMN (MING.NO), Veidekke (VEI.NO), Public Property Invest (PUBLI.NO), Solstad Offshore (SOFF.NO), Smartoptics Group (SMOP.NO), MediStim (MEDI.NO), PhotoCure (PHO.NO), Nekkar (NKR.NO), ArcticZymes Technologies (AZT.NO), Norsk Titanium (NTI.NO), Tekna Holding (TEKNA.NO)

          • DACH: Rheinmetall (RHM.GR), OHB (OHB.GR), Aumovio (AMV0.GR), Deutz (DEZ.GR), Kontron (KTN.GR), Wacker Neuson (WAC.GR), SÜSS MicroTec (SMHN.GR), Jungheinrich (JUN3.GR), Rhoen-Klinikum (RHK.GR), PVA Te Pla (TPE.GR), SNP Schneider-Neureither & Partner (SHF.GR), SGL Carbon (SGL.GR), GFT Technologies (GFT.GR), Deutsche Beteiligungs (DBAN.GR), Hamborner REIT (HABA.GR), Elringklinger (ZIL2.GR), Westwing Group (WEW.GR), Leifheit (LEI.GR), Schloss Wachenheim (SWA.GR), EDAG Engineering Group (ED4.GR), R. Stahl (RSL2.GR), Mister Spex (MRX.GR), DEMIRE Deutsche Mittelstand Real Estate (DMRE.GR), Cherry (C3RY.GR), Lenzing (LNZ.AV), Valiant Holding (VATN.SW), Landis+Gyr Group (LAND.SW), Montana Aerospace (AERO.SW)

          • France: TotalEnergies EP Gabon (EC.FP), Valneva (VLA.FP)

          • Italy: Banca Monte dei Paschi di Siena (BMPS.IM), TERNA Rete Elettrica Nazionale (TRN.IM), Mediobanca (MB.IM), Banca Mediolanum (BMED.IM), Pirelli & C. (PIRC.IM), Azimut Holding (AZM.IM), Iveco Group (IVG.IM), Diasorin (DIA.IM), Brembo (BRE.IM), Cementir Holding (CEM.IM), Banca Ifis (IF.IM), Comer Industries (COM.IM), Intercos (ICOS.IM), D'Amico International Shipping (DIS.IM), Ascopiave (ASC.IM), IGD SIIIQ (IGD.IM)

          • Spain: Ferrovial (FER.SM), Melia Hotels International (MEL.SM), Construcciones y Auxiliar de Ferrocarriles (CAF.SM), Global Dominion Access (DOM.SM), Laboratorio Reig Jofre (RJF.SM)

          • Portugal: Redes Energeticas Nacionais (RENE.PL), The Navigator Co. (NVG.PL)

          • UK: Shell (SHEL.LN), Lion Finance Group (BGEO.LN), JD Sports Fashion (JD.LN), Helios Towers (HTWS.LN), HgCapital Trust (HGT.LN), Next 15 Group (NFG.LN)

        • Trading Update: Koninklijke BAM Groep (BAMNB.NA), ForFarmers (FFARM.NA), Exasol (EXL.GR), Klepierre (LI.FP), BioGaia (BIOG.B.SS), GomSpace Group (GOMX.SS), Corporación Acciona Energías Renovables (ANE.SM), Metlen Energy & Metals (MTLN.GA), Safilo Group (SFL.IM), InterContinental Hotels Group (IHG.LN), Coca-Cola HBC (CCH.LN), Harbour Energy (HBR.LN), Morgan Sindall Group (MGNS.LN), Rathbones Group (RAT.LN), S4 Capital (SFOR.LN)

        • CMD/Events: Anora Group (ANORA.FH), Lumo Homes (LUMO.FH), Nova Ljubljanska Banka dd (NLBR.SV), Piraeus Port Authority (PPA.GA) analyst meeting - Hellenic Fund and Management Assn

    • M&A

      • ROP.SW (Roche Holding) -- Roche to acquire PathAI for $750M upfront and additional milestone payments of up to $300M

      • ITRK.LN (Intertek Group) -- expected to turn down improved acquisition offer from EQT -- FT

      • DEC.LN (Diversified Energy) -- to acquire assets from Camino Natural Resources

      • ALL.LN (Atlantic Lithium) -- Zhejiang Huayou Cobalt to acquire Atlantic Lithium by way of an Australian scheme of arrangement for cash consideration of $0.25486/sh (£0.188/sh)

      • ESSITY.B.SS (Essity) -- initiates strategic review of Consumer Tissue business area

      • HBR.LN (Harbour Energy) -- Grupo Carso SAB de CV acquires additional 5% interest in Zama oil field for $75.25M

      • KTN.GR (Kontron) -- discloses potential public takeover bid by Ennoconn Corporation, after it became more than a 30% shareholder in part due to share buybacks; contemplates offering €23.50/sh

      • HTRO.SS (Hexatronic Group) -- agrees to acquire Superior Fiber & Data Services, Inc. for $29M (enterprise value) + additional potential earn out

      • ALATA.FP (Atari, Inc.) -- acquires complete and exclusive rights to first five Wizardry games and associated underlying IP; terms undisclosed

    • Healthcare

      • NOVO.B.DC (Novo Nordisk) -- NICE recommends Novo Nordisk's Wegovy for reducing risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

      • GSK.LN (GSK Plc) -- SiranBio (private) outlicenses cardiometabolic siRNA oligonucleotide to GSK for up to $1B+ (earlier, timing uncertain)

      • SAN.FP (Sanofi) -- asks FDA to pull teplizumab from CNPV program - STAT News, citing sources

      • ZEAL.DC (Zealand Pharma) -- initiates $200M share buy-back program

      • ORNBV.FH (Orion) -- FDA approves Tessie for noise aversion and separation anxiety in dogs

    • Other

      • AIR.FP (Airbus SE) -- Airbus confirms AirAsia places order for 150 A220s

      • DBK.GR (Deutsche Bank) -- sets new timeline for clients to provide thermal coal transition plans

      • PNDORA.DC (Pandora) -- adds carbon footprint labelling for lab grown diamonds

      • JDW.LN (JD Wetherspoon) -- comments on Michael O'Leary's proposed two drink limit at airports

      • DEC.LN (Diversified Energy) -- SEC filing: 10-Q

      • TRST.LN (Trustpilot Group) -- Transcript Intelligence: Trustpilot Group Capital Markets Day

  • Key rating changes

    • Downgrades

      • IFX.GR (Infineon Technologies) -- to neutral from outperform at Oddo

      • REL.LN (RELX) -- to equal-weight from overweight at Morgan Stanley

      • ROVI.SM (Laboratorios Farmaceuticos Rovi, S.A.) -- to neutral from outperform at BNP Paribas Exane

    • Initiations

      • SOBI.SS (Swedish Orphan Biovitrum) -- buy at HC Wainwright

      • CHG.GR (CHAPTERS Group) -- buy at Berenberg

  • Data

    • Nikkei +5.98% to 63070.23

    • Hang Seng +1.34% to 26565.62

    • Shanghai Composite +0.38% to 4176.15

    • S&P futures +4.3 vs prior close of 7389.5

    • €-$ +0.0004 or +0.03% to 1.1752

    • $-¥ (0.02) or (0.02%) to 156.37

    • €-¥ +0.01 or +0.01% to 183.74

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.